Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Jacqueline S. Garcia, Haesook T Kim, Jennifer Brock, H. Moses Murdock, Corey S. Cutler, Daniel J. DeAngelo, Christopher J. Gibson, Mahasweta Gooptu, Vincent Ho, John Koreth, Marlise R. Luskin, Sarah Nikiforow, Rizwan Romee, Roman M Shapiro, Richard M. Stone, Martha Wadleigh, Eric S. Winer, Michela Ansuinelli, Eliza Elliot, Geoffrey Fell, Hannah Karp, Jeremy Ryan, Anthony G. Letai, Coleman Lindsley, Robert J Soiffer, Joseph H. Antin, Fiona Loschi, Jerome Ritz
Institutions: Dana-Farber Cancer Institute, Harvard University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310103753